IQVIA’s Jon Resnick Honored on 2018 PharmaVOICE 100 List
Published: Aug 01, 2018
“IQVIA has created platforms driving collaborations across payers, providers, and life sciences that will ultimately help patients. I am very proud that Jon who has been at the forefront of these efforts has been recognized for his leadership in advancing the industry’s adoption of real-world evidence,” said IQVIA Chairman and CEO Ari Bousbib.
Resnick, who was nominated by John Hervey, CEO of healthcare data and analytics company Cota Inc., has led the transformation of the way real-world evidence is generated and applied using advances such as machine learning, federated platforms, novel methodologies, and SaaS technologies. By bringing new data sources, deeper scientific expertise, and purpose-built technologies to solve complex challenges, IQVIA teams are offering breakthrough solutions across product lifecycles from R&D effectiveness to innovative contracting to more precise commercialization models. They also work directly with public health organizations, providers and other stakeholders to champion a cross-stakeholder collaborative approach to understand, measure and optimize value and patient outcomes spanning the healthcare system.
“As I have come to know Jon, it has become clear that I am not the only one who has benefited from his strategic thinking,” said Hervey. “For more than a decade, healthcare technology and analytics have been a passion for him. Jon has proven himself to be an adaptive leader who excels at bringing diverse teams together to pursue a common goal. The breadth of his experience and innovative thinking will enable us to leverage the insights derived from real-world evidence to make a positive impact on the future of healthcare.”
The annual PharmaVOICE 100 list celebrates inspirational, motivational, and transformative individuals in life sciences who positively impact their colleagues, peers, organizations, and the industry. These individuals think bigger, do more, and lead with passion and integrity. To read the PharmaVOICE profiles, visit www.pharmavoice.com.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.